Details of the Drug

General Information of Drug (ID: DMZMSCT)

Drug Name
Cilostazol
Synonyms
cilostazol; 73963-72-1; Pletal; Cilostazole; Pletaal; Cilostazolum; OPC-13013; Cilostazolum [INN-Latin]; OPC-21; OPC 13013; OPC 21; UNII-N7Z035406B; CHEBI:31401; C20H27N5O2; 6-(4-(1-Cyclohexyl-1H-tetrazol-5-yl)butoxy)-3,4-dihydro-2(1H)-quinolinone; BRN 3632107; 6-[4-(1-cyclohexyltetrazol-5-yl)butoxy]-3,4-dihydro-1H-quinolin-2-one; 6-(4-(1-cyclohexyl-1H-tetrazol-5-yl)butoxy)-3,4-dihydroquinolin-2(1H)-one; 3,4-Dihydro-6-(4-(1-cyclohexyl-1H-tetrazol-5-yl)butoxy)-2(1H)-quinolinone; MLS000028470; Cilostazole; Otsuka brand of cilostazol; C 0737; CL23867; Cilostazol [INN:JAN]; Pleta (TN); Pletal (TN); Pletal, Cilostazol; Cilostazol (JP15/USAN/INN); 6-(4-(1-Cyclohexyl-1H-tetrazol-5-yl)butoxy)-3,4-dihydrocarbostyril; 6-(4-(1-Cyclohexyl-1H-tetrazol-5-yl)butoxyl)-3,4-dihydrocarobostyril; 6-[4-(1-Cyclohexyl-1H-tetrazol-5-yl)-butoxy]-3,4-dihydro-2(1H)-quinolinone; 6-[4-(1-cyclohexyl-1H-tetrazol-5-yl)butoxy]-3,4-dihydroquinolin-2(1H)-one
Indication
Disease Entry ICD 11 Status REF
Intermittent claudication BD40.00 Approved [1], [2]
Therapeutic Class
Vasodilator Agents
Drug Type
Small molecular drug
Structure
3D MOL 2D MOL
#Ro5 Violations (Lipinski): 0 Molecular Weight (mw) 369.5
Topological Polar Surface Area (xlogp) 3.1
Rotatable Bond Count (rotbonds) 7
Hydrogen Bond Donor Count (hbonddonor) 1
Hydrogen Bond Acceptor Count (hbondacc) 5
ADMET Property
BDDCS Class
Biopharmaceutics Drug Disposition Classification System (BDDCS) Class 2: low solubility and high permeability [3]
Half-life
The concentration or amount of drug in body reduced by one-half in 11 - 13 hours [4]
Metabolism
The drug is metabolized via the hepatic [5]
MRTD
The Maximum Recommended Therapeutic Dose (MRTD) of drug that ensured maximising efficacy and moderate side effect is 7.733 micromolar/kg/day [6]
Water Solubility
The ability of drug to dissolve in water is measured as 0.003 mg/mL [3]
Chemical Identifiers
Formula
C20H27N5O2
IUPAC Name
6-[4-(1-cyclohexyltetrazol-5-yl)butoxy]-3,4-dihydro-1H-quinolin-2-one
Canonical SMILES
C1CCC(CC1)N2C(=NN=N2)CCCCOC3=CC4=C(C=C3)NC(=O)CC4
InChI
InChI=1S/C20H27N5O2/c26-20-12-9-15-14-17(10-11-18(15)21-20)27-13-5-4-8-19-22-23-24-25(19)16-6-2-1-3-7-16/h10-11,14,16H,1-9,12-13H2,(H,21,26)
InChIKey
RRGUKTPIGVIEKM-UHFFFAOYSA-N
Cross-matching ID
PubChem CID
2754
ChEBI ID
CHEBI:31401
CAS Number
73963-72-1
DrugBank ID
DB01166
TTD ID
D03VPC
VARIDT ID
DR01322
INTEDE ID
DR0324
ACDINA ID
D00129

Molecular Interaction Atlas of This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Phosphodiesterase 3 (PDE3) TTZCG4L NOUNIPROTAC Modulator [7]
Phosphodiesterase 3A (PDE3A) TT06AWU PDE3A_HUMAN Inhibitor [8]

Drug Transporter (DTP)
DTP Name DTP ID UniProt ID MOA REF
Organic anion transporting polypeptide 1B1 (SLCO1B1) DT3D8F0 SO1B1_HUMAN Substrate [9]
Organic anion transporting polypeptide 1B3 (SLCO1B3) DT9C1TS SO1B3_HUMAN Substrate [9]
Organic anion transporter 3 (SLC22A8) DTVP67E S22A8_HUMAN Substrate [10]

Drug-Metabolizing Enzyme (DME)
DME Name DME ID UniProt ID MOA REF
Cytochrome P450 3A4 (CYP3A4)
Main DME 		DE4LYSA CP3A4_HUMAN Substrate [11]
Cytochrome P450 2D6 (CYP2D6) DECB0K3 CP2D6_HUMAN Substrate [11]
Mephenytoin 4-hydroxylase (CYP2C19) DEGTFWK CP2CJ_HUMAN Substrate [11]
Cytochrome P450 1A2 (CYP1A2) DEJGDUW CP1A2_HUMAN Substrate [11]
Cytochrome P450 3A5 (CYP3A5) DEIBDNY CP3A5_HUMAN Substrate [11]
Cytochrome P450 3A7 (CYP3A7) DERD86B CP3A7_HUMAN Substrate [11]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

Molecular Expression Atlas of This Drug

The Studied Disease Intermittent claudication
ICD Disease Classification BD40.00
Molecule Name Molecule Type Gene Name p-value Fold-Change Z-score
Phosphodiesterase 3A (PDE3A) DTT PDE3A 3.33E-01 1.35E-02 0.14
Organic anion transporter 3 (SLC22A8) DTP OAT3 3.89E-02 6.02E-02 4.19E-01
Organic anion transporting polypeptide 1B3 (SLCO1B3) DTP OATP1B3 4.64E-01 3.84E-02 2.91E-01
Organic anion transporting polypeptide 1B1 (SLCO1B1) DTP OATP1B1 2.66E-02 2.54E-02 2.28E-01
Cytochrome P450 1A2 (CYP1A2) DME CYP1A2 6.75E-01 4.94E-02 4.06E-01
Cytochrome P450 3A5 (CYP3A5) DME CYP3A5 1.38E-02 1.07E-01 8.83E-01
Mephenytoin 4-hydroxylase (CYP2C19) DME CYP2C19 6.62E-01 1.75E-02 1.07E-01
Cytochrome P450 2D6 (CYP2D6) DME CYP2D6 6.76E-03 -1.19E-01 -1.54E+00
Cytochrome P450 3A4 (CYP3A4) DME CYP3A4 4.50E-03 -5.35E-02 -4.77E-01
Molecular Expression Atlas (MEA) Jump to Detail Molecular Expression Atlas of This Drug

Drug-Drug Interaction (DDI) Information of This Drug

Coadministration of a Drug Treating the Disease Different from Cilostazol (Comorbidity)
DDI Drug Name DDI Drug ID Severity Mechanism Comorbidity REF
Ivosidenib DM8S6T7 Major Increased risk of prolong QT interval by the combination of Cilostazol and Ivosidenib. Acute myeloid leukaemia [2A60] [100]
Midostaurin DMI6E0R Moderate Increased risk of prolong QT interval by the combination of Cilostazol and Midostaurin. Acute myeloid leukaemia [2A60] [101]
Idarubicin DMM0XGL Moderate Increased risk of prolong QT interval by the combination of Cilostazol and Idarubicin. Acute myeloid leukaemia [2A60] [101]
Arn-509 DMT81LZ Moderate Increased risk of prolong QT interval by the combination of Cilostazol and Arn-509. Acute myeloid leukaemia [2A60] [102]
Gilteritinib DMWQ4MZ Moderate Increased risk of prolong QT interval by the combination of Cilostazol and Gilteritinib. Acute myeloid leukaemia [2A60] [103]
Oliceridine DM6MDCF Moderate Increased risk of prolong QT interval by the combination of Cilostazol and Oliceridine. Acute pain [MG31] [101]
Ivabradine DM0L594 Major Increased risk of ventricular arrhythmias by the combination of Cilostazol and Ivabradine. Angina pectoris [BA40] [102]
Bepridil DM0RKS4 Major Increased risk of prolong QT interval by the combination of Cilostazol and Bepridil. Angina pectoris [BA40] [101]
Dronedarone DMA8FS5 Major Decreased metabolism of Cilostazol caused by Dronedarone mediated inhibition of CYP450 enzyme. Angina pectoris [BA40] [102]
Bedaquiline DM3906J Major Increased risk of prolong QT interval by the combination of Cilostazol and Bedaquiline. Antimicrobial drug resistance [MG50-MG52] [104]
Posaconazole DMUL5EW Major Decreased metabolism of Cilostazol caused by Posaconazole mediated inhibition of CYP450 enzyme. Aspergillosis [1F20] [102]
Levalbuterol DM5YBO1 Moderate Increased risk of prolong QT interval by the combination of Cilostazol and Levalbuterol. Asthma [CA23] [105]
Pirbuterol DMI5678 Moderate Increased risk of ventricular arrhythmias by the combination of Cilostazol and Pirbuterol. Asthma [CA23] [106]
Lisdexamfetamine DM6W8V5 Moderate Increased risk of prolong QT interval by the combination of Cilostazol and Lisdexamfetamine. Attention deficit hyperactivity disorder [6A05] [102]
Dalfopristin DM4LTKV Major Decreased metabolism of Cilostazol caused by Dalfopristin mediated inhibition of CYP450 enzyme. Bacterial infection [1A00-1C4Z] [102]
Clarithromycin DM4M1SG Major Decreased metabolism of Cilostazol caused by Clarithromycin mediated inhibition of CYP450 enzyme. Bacterial infection [1A00-1C4Z] [102]
Sparfloxacin DMB4HCT Major Increased risk of prolong QT interval by the combination of Cilostazol and Sparfloxacin. Bacterial infection [1A00-1C4Z] [107]
Troleandomycin DMUZNIG Major Decreased metabolism of Cilostazol caused by Troleandomycin mediated inhibition of CYP450 enzyme. Bacterial infection [1A00-1C4Z] [102]
Eribulin DM1DX4Q Moderate Increased risk of prolong QT interval by the combination of Cilostazol and Eribulin. Breast cancer [2C60-2C6Y] [101]
Lapatinib DM3BH1Y Moderate Decreased metabolism of Cilostazol caused by Lapatinib mediated inhibition of CYP450 enzyme. Breast cancer [2C60-2C6Y] [108]
Tucatinib DMBESUA Major Decreased metabolism of Cilostazol caused by Tucatinib mediated inhibition of CYP450 enzyme. Breast cancer [2C60-2C6Y] [102]
Palbociclib DMD7L94 Moderate Decreased metabolism of Cilostazol caused by Palbociclib mediated inhibition of CYP450 enzyme. Breast cancer [2C60-2C6Y] [108]
Bosutinib DMTI8YE Moderate Increased risk of prolong QT interval by the combination of Cilostazol and Bosutinib. Breast cancer [2C60-2C6Y] [102]
PF-04449913 DMSB068 Moderate Increased risk of prolong QT interval by the combination of Cilostazol and PF-04449913. Chronic myelomonocytic leukaemia [2A40] [109]
Olodaterol DM62B78 Moderate Increased risk of ventricular arrhythmias by the combination of Cilostazol and Olodaterol. Chronic obstructive pulmonary disease [CA22] [106]
Vilanterol DMF5EK1 Moderate Increased risk of ventricular arrhythmias by the combination of Cilostazol and Vilanterol. Chronic obstructive pulmonary disease [CA22] [105]
Indacaterol DMQJHR7 Moderate Increased risk of prolong QT interval by the combination of Cilostazol and Indacaterol. Chronic obstructive pulmonary disease [CA22] [106]
Arformoterol DMYM974 Moderate Increased risk of ventricular arrhythmias by the combination of Cilostazol and Arformoterol. Chronic obstructive pulmonary disease [CA22] [106]
Levomilnacipran DMV26S8 Moderate Increased risk of bleeding by the combination of Cilostazol and Levomilnacipran. Chronic pain [MG30] [110]
Regorafenib DMHSY1I Major Increased risk of bleeding by the combination of Cilostazol and Regorafenib. Colorectal cancer [2B91] [102]
Intedanib DMSTA36 Moderate Increased risk of bleeding by the combination of Cilostazol and Intedanib. Colorectal cancer [2B91] [111]
Sevoflurane DMC9O43 Moderate Increased risk of prolong QT interval by the combination of Cilostazol and Sevoflurane. Corneal disease [9A76-9A78] [101]
Probucol DMVZQ2M Moderate Increased risk of prolong QT interval by the combination of Cilostazol and Probucol. Coronary atherosclerosis [BA80] [101]
Ardeparin DMYRX8B Major Increased risk of bleeding by the combination of Cilostazol and Ardeparin. Coronary thrombosis [BA43] [112]
Pasireotide DMHM7JS Major Increased risk of prolong QT interval by the combination of Cilostazol and Pasireotide. Cushing syndrome [5A70] [101]
Osilodrostat DMIJC9X Moderate Decreased metabolism of Cilostazol caused by Osilodrostat mediated inhibition of CYP450 enzyme. Cushing syndrome [5A70] [108]
Lumacaftor DMCLWDJ Moderate Increased metabolism of Cilostazol caused by Lumacaftor mediated induction of CYP450 enzyme. Cystic fibrosis [CA25] [113]
Ivacaftor DMZC1HS Moderate Decreased metabolism of Cilostazol caused by Ivacaftor mediated inhibition of CYP450 enzyme. Cystic fibrosis [CA25] [108]
MK-8228 DMOB58Q Major Decreased metabolism of Cilostazol caused by MK-8228 mediated inhibition of CYP450 enzyme. Cytomegaloviral disease [1D82] [102]
Danaparoid DM6CLBN Major Increased risk of bleeding by the combination of Cilostazol and Danaparoid. Deep vein thrombosis [BD71] [112]
Rivaroxaban DMQMBZ1 Major Increased risk of bleeding by the combination of Cilostazol and Rivaroxaban. Deep vein thrombosis [BD71] [114]
Vilazodone DM4LECQ Moderate Increased risk of bleeding by the combination of Cilostazol and Vilazodone. Depression [6A70-6A7Z] [110]
Vortioxetine DM6F1PU Moderate Increased risk of bleeding by the combination of Cilostazol and Vortioxetine. Depression [6A70-6A7Z] [110]
Milnacipran DMBFE74 Moderate Increased risk of bleeding by the combination of Cilostazol and Milnacipran. Depression [6A70-6A7Z] [110]
Desvenlafaxine DMHD4PE Moderate Increased risk of bleeding by the combination of Cilostazol and Desvenlafaxine. Depression [6A70-6A7Z] [110]
Heme DMGC287 Moderate Increased risk of bleeding by the combination of Cilostazol and Heme. Discovery agent [N.A.] [115]
Apigenin DMI3491 Minor Increased risk of bleeding by the combination of Cilostazol and Apigenin. Discovery agent [N.A.] [116]
Tetrabenazine DMYWQ0O Moderate Increased risk of prolong QT interval by the combination of Cilostazol and Tetrabenazine. Dissociative neurological symptom disorder [6B60] [101]
Deutetrabenazine DMUPFLI Moderate Increased risk of prolong QT interval by the combination of Cilostazol and Deutetrabenazine. Dystonic disorder [8A02] [117]
Ingrezza DMVPLNC Moderate Additive CNS depression effects by the combination of Cilostazol and Ingrezza. Dystonic disorder [8A02] [118]
Cenobamate DMGOVHA Moderate Decreased metabolism of Cilostazol caused by Cenobamate mediated inhibition of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [108]
Brivaracetam DMSEPK8 Minor Decreased metabolism of Cilostazol caused by Brivaracetam mediated inhibition of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [102]
Eslicarbazepine DMZREFQ Moderate Decreased metabolism of Cilostazol caused by Eslicarbazepine mediated inhibition of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [108]
Solifenacin DMG592Q Moderate Increased risk of prolong QT interval by the combination of Cilostazol and Solifenacin. Functional bladder disorder [GC50] [101]
Itraconazole DMCR1MV Major Decreased metabolism of Cilostazol caused by Itraconazole mediated inhibition of CYP450 enzyme. Fungal infection [1F29-1F2F] [102]
Sunitinib DMCBJSR Moderate Increased risk of prolong QT interval by the combination of Cilostazol and Sunitinib. Gastrointestinal stromal tumour [2B5B] [101]
Avapritinib DMK2GZX Major Increased risk of bleeding by the combination of Cilostazol and Avapritinib. Gastrointestinal stromal tumour [2B5B] [102]
Boceprevir DMBSHMF Major Decreased metabolism of Cilostazol caused by Boceprevir mediated inhibition of CYP450 enzyme. Hepatitis virus infection [1E50-1E51] [102]
Telaprevir DMMRV29 Major Decreased metabolism of Cilostazol caused by Telaprevir mediated inhibition of CYP450 enzyme. Hepatitis virus infection [1E50-1E51] [102]
Rifapentine DMCHV4I Moderate Increased metabolism of Cilostazol caused by Rifapentine mediated induction of CYP450 enzyme. HIV-infected patients with tuberculosis [1B10-1B14] [119]
Fosamprenavir DM4W9B3 Major Decreased metabolism of Cilostazol caused by Fosamprenavir mediated inhibition of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [102]
Fostemsavir DM50ILT Moderate Increased risk of prolong QT interval by the combination of Cilostazol and Fostemsavir. Human immunodeficiency virus disease [1C60-1C62] [120]
Cobicistat DM6L4H2 Major Decreased metabolism of Cilostazol caused by Cobicistat mediated inhibition of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [102]
Saquinavir DMG814N Major Decreased metabolism of Cilostazol caused by Saquinavir mediated inhibition of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [102]
Rilpivirine DMJ0QOW Moderate Increased risk of prolong QT interval by the combination of Cilostazol and Rilpivirine. Human immunodeficiency virus disease [1C60-1C62] [101]
Darunavir DMN3GCH Major Decreased metabolism of Cilostazol caused by Darunavir mediated inhibition of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [102]
BMS-201038 DMQTAGO Moderate Decreased metabolism of Cilostazol caused by BMS-201038 mediated inhibition of CYP450 enzyme. Hyper-lipoproteinaemia [5C80] [121]
Levamlodipine DM92S6N Moderate Decreased metabolism of Cilostazol caused by Levamlodipine mediated inhibition of CYP450 enzyme. Hypertension [BA00-BA04] [108]
Berotralstat DMWA2DZ Major Decreased metabolism of Cilostazol caused by Berotralstat mediated inhibition of CYP450 enzyme. Innate/adaptive immunodeficiency [4A00] [102]
Polyethylene glycol DM4I1JP Moderate Increased risk of ventricular arrhythmias by the combination of Cilostazol and Polyethylene glycol. Irritable bowel syndrome [DD91] [102]
Phenolphthalein DM5SICT Moderate Increased risk of ventricular arrhythmias by the combination of Cilostazol and Phenolphthalein. Irritable bowel syndrome [DD91] [101]
Crizotinib DM4F29C Major Decreased metabolism of Cilostazol caused by Crizotinib mediated inhibition of CYP450 enzyme. Lung cancer [2C25] [102]
Ceritinib DMB920Z Major Decreased metabolism of Cilostazol caused by Ceritinib mediated inhibition of CYP450 enzyme. Lung cancer [2C25] [102]
PF-06463922 DMKM7EW Moderate Increased metabolism of Cilostazol caused by PF-06463922 mediated induction of CYP450 enzyme. Lung cancer [2C25] [122]
Osimertinib DMRJLAT Major Increased risk of prolong QT interval by the combination of Cilostazol and Osimertinib. Lung cancer [2C25] [123]
Selpercatinib DMZR15V Moderate Decreased metabolism of Cilostazol caused by Selpercatinib mediated inhibition of CYP450 enzyme. Lung cancer [2C25] [108]
Halofantrine DMOMK1V Major Increased risk of prolong QT interval by the combination of Cilostazol and Halofantrine. Malaria [1F40-1F45] [124]
Hydroxychloroquine DMSIVND Major Increased risk of prolong QT interval by the combination of Cilostazol and Hydroxychloroquine. Malaria [1F40-1F45] [125]
Inotuzumab ozogamicin DMAC130 Moderate Increased risk of prolong QT interval by the combination of Cilostazol and Inotuzumab ozogamicin. Malignant haematopoietic neoplasm [2B33] [102]
Calaspargase pegol DMQZBXI Moderate Increased risk of bleeding by the combination of Cilostazol and Calaspargase pegol. Malignant haematopoietic neoplasm [2B33] [126]
Idelalisib DM602WT Major Decreased metabolism of Cilostazol caused by Idelalisib mediated inhibition of CYP450 enzyme. Mature B-cell leukaemia [2A82] [102]
IPI-145 DMWA24P Major Decreased metabolism of Cilostazol caused by IPI-145 mediated inhibition of CYP450 enzyme. Mature B-cell leukaemia [2A82] [102]
Arsenic trioxide DM61TA4 Major Increased risk of prolong QT interval by the combination of Cilostazol and Arsenic trioxide. Mature B-cell lymphoma [2A85] [127]
Acalabrutinib DM7GCVW Major Increased risk of bleeding by the combination of Cilostazol and Acalabrutinib. Mature B-cell lymphoma [2A85] [128]
Ibrutinib DMHZCPO Major Increased risk of bleeding by the combination of Cilostazol and Ibrutinib. Mature B-cell lymphoma [2A85] [129]
Ponatinib DMYGJQO Major Increased risk of bleeding by the combination of Cilostazol and Ponatinib. Mature B-cell lymphoma [2A85] [130]
Vemurafenib DM62UG5 Major Increased risk of prolong QT interval by the combination of Cilostazol and Vemurafenib. Melanoma [2C30] [101]
LGX818 DMNQXV8 Moderate Increased risk of prolong QT interval by the combination of Cilostazol and LGX818. Melanoma [2C30] [131]
Dabrafenib DMX6OE3 Moderate Increased metabolism of Cilostazol caused by Dabrafenib mediated induction of CYP450 enzyme. Melanoma [2C30] [102]
Danazol DML8KTN Moderate Decreased metabolism of Cilostazol caused by Danazol mediated inhibition of CYP450 enzyme. Menstrual cycle bleeding disorder [GA20] [108]
Siponimod DM2R86O Major Increased risk of ventricular arrhythmias by the combination of Cilostazol and Siponimod. Multiple sclerosis [8A40] [132]
Fingolimod DM5JVAN Major Increased risk of ventricular arrhythmias by the combination of Cilostazol and Fingolimod. Multiple sclerosis [8A40] [101]
Ozanimod DMT6AM2 Major Increased risk of ventricular arrhythmias by the combination of Cilostazol and Ozanimod. Multiple sclerosis [8A40] [133]
Romidepsin DMT5GNL Moderate Increased risk of prolong QT interval by the combination of Cilostazol and Romidepsin. Mycosis fungoides [2B01] [101]
Fedratinib DM4ZBK6 Major Decreased metabolism of Cilostazol caused by Fedratinib mediated inhibition of CYP450 enzyme. Myeloproliferative neoplasm [2A20] [102]
Nilotinib DM7HXWT Moderate Decreased metabolism of Cilostazol caused by Nilotinib mediated inhibition of CYP450 enzyme. Myeloproliferative neoplasm [2A20] [108]
Dasatinib DMJV2EK Major Increased risk of bleeding by the combination of Cilostazol and Dasatinib. Myeloproliferative neoplasm [2A20] [134]
Omacetaxine mepesuccinate DMPU2WX Major Increased risk of bleeding by the combination of Cilostazol and Omacetaxine mepesuccinate. Myeloproliferative neoplasm [2A20] [135]
Netupitant DMEKAYI Major Decreased metabolism of Cilostazol caused by Netupitant mediated inhibition of CYP450 enzyme. Nausea/vomiting [MD90] [102]
Entrectinib DMMPTLH Moderate Decreased metabolism of Cilostazol caused by Entrectinib mediated inhibition of CYP450 enzyme. Non-small cell lung cancer [2C25] [108]
Dexfenfluramine DMJ7YDS Moderate Increased risk of bleeding by the combination of Cilostazol and Dexfenfluramine. Obesity [5B80-5B81] [110]
Levomethadyl Acetate DM06HG5 Major Increased risk of prolong QT interval by the combination of Cilostazol and Levomethadyl Acetate. Opioid use disorder [6C43] [102]
Nepafenac DMYK490 Moderate Increased risk of bleeding by the combination of Cilostazol and Nepafenac. Osteoarthritis [FA00-FA05] [136]
Rucaparib DM9PVX8 Moderate Decreased metabolism of Cilostazol caused by Rucaparib mediated inhibition of CYP450 enzyme. Ovarian cancer [2C73] [108]
MK-4827 DMLYGH4 Moderate Increased risk of bleeding by the combination of Cilostazol and MK-4827. Ovarian cancer [2C73] [102]
Triclabendazole DMPWGBR Moderate Increased risk of prolong QT interval by the combination of Cilostazol and Triclabendazole. Parasitic worm infestation [1F90] [101]
Pimavanserin DMR7IVC Moderate Increased risk of prolong QT interval by the combination of Cilostazol and Pimavanserin. Parkinsonism [8A00] [137]
Abametapir DM2RX0I Moderate Decreased metabolism of Cilostazol caused by Abametapir mediated inhibition of CYP450 enzyme. Pediculosis [1G00] [138]
Macimorelin DMQYJIR Major Increased risk of prolong QT interval by the combination of Cilostazol and Macimorelin. Pituitary gland disorder [5A60-5A61] [139]
Lefamulin DME6G97 Moderate Decreased metabolism of Cilostazol caused by Lefamulin mediated inhibition of CYP450 enzyme. Pneumonia [CA40] [140]
Lonafarnib DMGM2Z6 Major Decreased metabolism of Cilostazol caused by Lonafarnib mediated inhibition of CYP450 enzyme. Premature ageing appearance [LD2B] [102]
Degarelix DM3O8QY Moderate Increased risk of prolong QT interval by the combination of Cilostazol and Degarelix. Prostate cancer [2C82] [102]
ABIRATERONE DM8V75C Moderate Increased risk of prolong QT interval by the combination of Cilostazol and ABIRATERONE. Prostate cancer [2C82] [102]
Enzalutamide DMGL19D Moderate Increased risk of prolong QT interval by the combination of Cilostazol and Enzalutamide. Prostate cancer [2C82] [102]
Relugolix DMK7IWL Moderate Increased risk of prolong QT interval by the combination of Cilostazol and Relugolix. Prostate cancer [2C82] [102]
Levomepromazine DMIKFEL Moderate Increased risk of prolong QT interval by the combination of Cilostazol and Levomepromazine. Psychotic disorder [6A20-6A25] [101]
Epoprostenol DMUTYR2 Moderate Increased risk of bleeding by the combination of Cilostazol and Epoprostenol. Pulmonary hypertension [BB01] [141]
Temsirolimus DMS104F Moderate Increased plasma concentrations of Cilostazol and Temsirolimus due to competitive inhibition of the same metabolic pathway. Renal cell carcinoma [2C90] [142]
Quetiapine DM1N62C Moderate Increased risk of prolong QT interval by the combination of Cilostazol and Quetiapine. Schizophrenia [6A20] [101]
Aripiprazole DM3NUMH Moderate Increased risk of prolong QT interval by the combination of Cilostazol and Aripiprazole. Schizophrenia [6A20] [132]
Iloperidone DM6AUFY Major Increased risk of prolong QT interval by the combination of Cilostazol and Iloperidone. Schizophrenia [6A20] [101]
Paliperidone DM7NPJS Moderate Increased risk of prolong QT interval by the combination of Cilostazol and Paliperidone. Schizophrenia [6A20] [101]
Amisulpride DMSJVAM Major Increased risk of prolong QT interval by the combination of Cilostazol and Amisulpride. Schizophrenia [6A20] [143]
Asenapine DMSQZE2 Moderate Increased risk of prolong QT interval by the combination of Cilostazol and Asenapine. Schizophrenia [6A20] [101]
Voxelotor DMCS6M5 Moderate Decreased metabolism of Cilostazol caused by Voxelotor mediated inhibition of CYP450 enzyme. Sickle-cell disorder [3A51] [108]
Larotrectinib DM26CQR Moderate Decreased metabolism of Cilostazol caused by Larotrectinib mediated inhibition of CYP450 enzyme. Solid tumour/cancer [2A00-2F9Z] [108]
Armodafinil DMGB035 Moderate Decreased metabolism of Cilostazol caused by Armodafinil mediated inhibition of CYP450 enzyme. Solid tumour/cancer [2A00-2F9Z] [108]
LEE011 DMMX75K Major Decreased metabolism of Cilostazol caused by LEE011 mediated inhibition of CYP450 enzyme. Solid tumour/cancer [2A00-2F9Z] [102]
Vandetanib DMRICNP Major Increased risk of prolong QT interval by the combination of Cilostazol and Vandetanib. Solid tumour/cancer [2A00-2F9Z] [101]
Triptorelin DMTK4LS Moderate Increased risk of prolong QT interval by the combination of Cilostazol and Triptorelin. Solid tumour/cancer [2A00-2F9Z] [102]
Pitolisant DM8RFNJ Moderate Increased risk of prolong QT interval by the combination of Cilostazol and Pitolisant. Somnolence [MG42] [102]
Telavancin DM58VQX Moderate Increased risk of prolong QT interval by the combination of Cilostazol and Telavancin. Staphylococcal/streptococcal disease [1B5Y] [101]
Apixaban DM89JLN Major Increased risk of bleeding by the combination of Cilostazol and Apixaban. Thrombosis [DB61-GB90] [102]
Brilinta DMBR01X Moderate Increased risk of bleeding by the combination of Cilostazol and Brilinta. Thrombosis [DB61-GB90] [102]
Lenvatinib DMB1IU4 Moderate Increased risk of prolong QT interval by the combination of Cilostazol and Lenvatinib. Thyroid cancer [2D10] [101]
Cabozantinib DMIYDT4 Major Increased risk of bleeding by the combination of Cilostazol and Cabozantinib. Thyroid cancer [2D10] [144]
Trimeprazine DMEMV9D Moderate Increased risk of prolong QT interval by the combination of Cilostazol and Trimeprazine. Vasomotor/allergic rhinitis [CA08] [145]
Betrixaban DM2C4RF Major Increased risk of bleeding by the combination of Cilostazol and Betrixaban. Venous thromboembolism [BD72] [146]
Propafenone DMPIBJK Moderate Increased risk of prolong QT interval by the combination of Cilostazol and Propafenone. Ventricular tachyarrhythmia [BC71] [101]
Flecainide DMSQDLE Moderate Increased risk of prolong QT interval by the combination of Cilostazol and Flecainide. Ventricular tachyarrhythmia [BC71] [101]
⏷ Show the Full List of 140 DDI Information of This Drug

Drug Inactive Ingredient(s) (DIG) and Formulation(s) of This Drug

DIG
DIG Name DIG ID PubChem CID Functional Classification
Sodium lauryl sulfate E00464 3423265 Emulsifying agent; Modified-release agent; Penetration agent; Solubilizing agent; Surfactant; lubricant
Beta-D-lactose E00099 6134 Diluent; Dry powder inhaler carrier; Lyophilization aid
Carmellose sodium E00625 Not Available Disintegrant
Crospovidone E00626 Not Available Disintegrant
Hypromellose E00634 Not Available Coating agent
Lactose monohydrate E00393 104938 Binding agent; Diluent; Dry powder inhaler carrier; Lyophilization aid
Magnesium stearate E00208 11177 lubricant
Povidone E00667 Not Available Binding agent; Coating agent; Disintegrant; Film/membrane-forming agent; Solubilizing agent; Suspending agent
Silicon dioxide E00670 Not Available Anticaking agent; Opacifying agent; Viscosity-controlling agent
Vinylpyrrolidone E00668 Not Available Binding agent; Coating agent; Disintegrant; Film/membrane-forming agent; Solubilizing agent; Suspending agent
⏷ Show the Full List of 10 Pharmaceutical Excipients of This Drug
Pharmaceutical Formulation
Formulation Name Drug Dosage Dosage Form Route
Cilostazol 100 mg tablet 100 mg Oral Tablet Oral
Cilostazol 50 mg tablet 50 mg Oral Tablet Oral
Jump to Detail Pharmaceutical Formulation Page of This Drug

References

1 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7148).
2 Emerging drugs in peripheral arterial disease. Expert Opin Emerg Drugs. 2006 Mar;11(1):75-90.
3 BDDCS applied to over 900 drugs
4 Trend Analysis of a Database of Intravenous Pharmacokinetic Parameters in Humans for 1352 Drug Compounds
5 FDA approval: ado-trastuzumab emtansine for the treatment of patients with HER2-positive metastatic breast cancer. Clin Cancer Res. 2014 Sep 1;20(17):4436-41.
6 Estimating the safe starting dose in phase I clinical trials and no observed effect level based on QSAR modeling of the human maximum recommended daily dose
7 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
8 A new generation of phosphodiesterase inhibitors: multiple molecular forms of phosphodiesterase and the potential for drug selectivity. J Med Chem. 1985 May;28(5):537-45.
9 Organic Anion-Transporting Polypeptide and Efflux Transporter-Mediated Hepatic Uptake and Biliary Excretion of Cilostazol and Its Metabolites in Rats and Humans. J Pharm Sci. 2017 Sep;106(9):2515-2523.
10 Aspirin and probenecid inhibit organic anion transporter 3-mediated renal uptake of cilostazol and probenecid induces metabolism of cilostazol in the rat. Drug Metab Dispos. 2014 Jun;42(6):996-1007.
11 Effects of CYP3A inhibition on the metabolism of cilostazol. Clin Pharmacokinet. 1999;37 Suppl 2:61-8.
12 Expression levels and activation of a PXR variant are directly related to drug resistance in osteosarcoma cell lines. Cancer. 2007 Mar 1;109(5):957-65.
13 Contribution of human hepatic cytochrome P450 isoforms to regioselective hydroxylation of steroid hormones. Xenobiotica. 1998 Jun;28(6):539-47.
14 Comprehensive evaluation of tamoxifen sequential biotransformation by the human cytochrome P450 system in vitro: prominent roles for CYP3A and CYP2D6. J Pharmacol Exp Ther. 2004 Sep;310(3):1062-75.
15 Isoform-specific regulation of cytochromes P450 expression by estradiol and progesterone. Drug Metab Dispos. 2013 Feb;41(2):263-9.
16 Metabolic interactions between acetaminophen (paracetamol) and two flavonoids, luteolin and quercetin, through in-vitro inhibition studies. J Pharm Pharmacol. 2017 Dec;69(12):1762-1772.
17 Potent mechanism-based inhibition of CYP3A4 by imatinib explains its liability to interact with CYP3A4 substrates. Br J Pharmacol. 2012 Apr;165(8):2787-98.
18 Effects of morin on the pharmacokinetics of etoposide in rats. Biopharm Drug Dispos. 2007 Apr;28(3):151-6.
19 The metabolism of zidovudine by human liver microsomes in vitro: formation of 3'-amino-3'-deoxythymidine. Biochem Pharmacol. 1994 Jul 19;48(2):267-76.
20 Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675.
21 Roles of cytochromes P450 1A2, 2A6, and 2C8 in 5-fluorouracil formation from tegafur, an anticancer prodrug, in human liver microsomes. Drug Metab Dispos. 2000 Dec;28(12):1457-63.
22 Effects of polyunsaturated fatty acids on prostaglandin synthesis and cyclooxygenase-mediated DNA adduct formation by heterocyclic aromatic amines in human adenocarcinoma colon cells. Mol Carcinog. 2004 Jul;40(3):180-8.
23 Endoxifen and other metabolites of tamoxifen inhibit human hydroxysteroid sulfotransferase 2A1 (hSULT2A1). Drug Metab Dispos. 2014 Nov;42(11):1843-50.
24 Cytochrome P450 1A2 (CYP1A2) activity and risk factors for breast cancer: a cross-sectional study. Breast Cancer Res. 2004;6(4):R352-65.
25 PharmGKB summary: pathways of acetaminophen metabolism at the therapeutic versus toxic doses. Pharmacogenet Genomics. 2015 Aug;25(8):416-26.
26 The effect of apigenin on pharmacokinetics of imatinib and its metabolite N-desmethyl imatinib in rats. Biomed Res Int. 2013;2013:789184.
27 The influence of metabolic gene polymorphisms on urinary 1-hydroxypyrene concentrations in Chinese coke oven workers. Sci Total Environ. 2007 Aug 1;381(1-3):38-46.
28 Identification of P450 enzymes involved in metabolism of verapamil in humans. Naunyn Schmiedebergs Arch Pharmacol. 1993 Sep;348(3):332-7.
29 Metabolism and metabolic inhibition of xanthotoxol in human liver microsomes. Evid Based Complement Alternat Med. 2016;2016:5416509.
30 Inhibitory effects of anticancer drugs on dextromethorphan-O-demethylase activity in human liver microsomes. Cancer Chemother Pharmacol. 1993;32(6):491-5.
31 Effect of genetic polymorphism on the metabolism of endogenous neuroactive substances, progesterone and p-tyramine, catalyzed by CYP2D6. Brain Res Mol Brain Res. 2004 Oct 22;129(1-2):117-23.
32 CYP2D6 polymorphisms and tamoxifen metabolism: clinical relevance. Curr Oncol Rep. 2010 Jan;12(1):7-15.
33 Inhibition of cytochrome P450 2D6: structure-activity studies using a series of quinidine and quinine analogues. Chem Res Toxicol. 2003 Apr;16(4):450-9.
34 Effects of propofol on human hepatic microsomal cytochrome P450 activities. Xenobiotica. 1998 Sep;28(9):845-53.
35 Pharmacogenetics of schizophrenia. Am J Med Genet. 2000 Spring;97(1):98-106.
36 Roles of CYP2A6 and CYP2B6 in nicotine C-oxidation by human liver microsomes. Arch Toxicol. 1999 Mar;73(2):65-70.
37 Structure-activity relationship for human cytochrome P450 substrates and inhibitors. Drug Metab Rev. 2002 Feb-May;34(1-2):69-82.
38 Drug related genetic polymorphisms affecting adverse reactions to methotrexate, vinblastine, doxorubicin and cisplatin in patients with urothelial cancer. J Urol. 2008 Dec;180(6):2389-95.
39 Human prostate CYP3A5: identification of a unique 5'-untranslated sequence and characterization of purified recombinant protein. Biochem Biophys Res Commun. 1999 Jul 14;260(3):676-81.
40 Polymorphisms in cytochrome P4503A5 (CYP3A5) may be associated with race and tumor characteristics, but not metabolism and side effects of tamoxifen in breast cancer patients. Cancer Lett. 2005 Jan 10;217(1):61-72.
41 Drug Interactions Flockhart Table
42 Induction of hepatic CYP2E1 by a subtoxic dose of acetaminophen in rats: increase in dichloromethane metabolism and carboxyhemoglobin elevation. Drug Metab Dispos. 2007 Oct;35(10):1754-8.
43 Urinary 6 beta-hydroxycortisol excretion in rheumatoid arthritis. Br J Rheumatol. 1997 Jan;36(1):54-8.
44 Clinical pharmacokinetics of imatinib. Clin Pharmacokinet. 2005;44(9):879-94.
45 Kinetics and regulation of cytochrome P450-mediated etoposide metabolism. Drug Metab Dispos. 2004 Sep;32(9):993-1000.
46 Differential mechanism-based inhibition of CYP3A4 and CYP3A5 by verapamil. Drug Metab Dispos. 2005 May;33(5):664-71.
47 The role of cytochrome P450 3A (CYP3A) isoform(s) in oxidative metabolism of testosterone and benzphetamine in human adult and fetal liver. J Steroid Biochem Mol Biol. 1993 Jan;44(1):61-7.
48 Summary of information on human CYP enzymes: human P450 metabolism data. Drug Metab Rev. 2002 Feb-May;34(1-2):83-448.
49 Prediction of cytochrome P450 3A inhibition by verapamil enantiomers and their metabolites. Drug Metab Dispos. 2004 Feb;32(2):259-66.
50 The role of human cytochrome P450 enzymes in the formation of 2-hydroxymetronidazole: CYP2A6 is the high affinity (low Km) catalyst. Drug Metab Dispos. 2013 Sep;41(9):1686-94.
51 High-dose rabeprazole/amoxicillin therapy as the second-line regimen after failure to eradicate H. pylori by triple therapy with the usual doses of a proton pump inhibitor, clarithromycin and amoxicillin. Hepatogastroenterology. 2003 Nov-Dec;50(54):2274-8.
52 Progesterone and testosterone hydroxylation by cytochromes P450 2C19, 2C9, and 3A4 in human liver microsomes. Arch Biochem Biophys. 1997 Oct 1;346(1):161-9.
53 Cytochrome P450 pharmacogenetics and cancer. Oncogene. 2006 Mar 13;25(11):1679-91.
54 CYP2C19*17 is associated with decreased breast cancer risk. Breast Cancer Res Treat. 2009 May;115(2):391-6.
55 Cytochromes of the P450 2C subfamily are the major enzymes involved in the O-demethylation of verapamil in humans. Naunyn Schmiedebergs Arch Pharmacol. 1995 Dec;353(1):116-21.
56 Diclofenac and its derivatives as tools for studying human cytochromes P450 active sites: particular efficiency and regioselectivity of P450 2Cs. Biochemistry. 1999 Oct 26;38(43):14264-70.
57 A mechanistic approach to antiepileptic drug interactions. Ann Pharmacother. 1998 May;32(5):554-63.
58 Organic anion-transporting polypeptide B (OATP-B) and its functional comparison with three other OATPs of human liver. Gastroenterology. 2001 Feb;120(2):525-33.
59 Possible involvement of multiple human cytochrome P450 isoforms in the liver metabolism of propofol. Br J Anaesth. 1998 Jun;80(6):788-95.
60 Preclinical Mouse Models To Study Human OATP1B1- and OATP1B3-Mediated Drug-Drug Interactions in Vivo. Mol Pharm. 2015 Dec 7;12(12):4259-69.
61 Organic anion transporting polypeptide 1B1: a genetically polymorphic transporter of major importance for hepatic drug uptake. Pharmacol Rev. 2011 Mar;63(1):157-81.
62 Contribution of OATP1B1 and OATP1B3 to the disposition of sorafenib and sorafenib-glucuronide. Clin Cancer Res. 2013 Mar 15;19(6):1458-66.
63 Identification of drugs and drug metabolites as substrates of multidrug resistance protein 2 (MRP2) using triple-transfected MDCK-OATP1B1-UGT1A1-MRP2 cells. Br J Pharmacol. 2012 Mar;165(6):1836-1847.
64 The effect of SLCO1B1*15 on the disposition of pravastatin and pitavastatin is substrate dependent: the contribution of transporting activity changes by SLCO1B1*15. Pharmacogenet Genomics. 2008 May;18(5):424-33.
65 Influence of SLCO1B1, 1B3, 2B1 and ABCC2 genetic polymorphisms on mycophenolic acid pharmacokinetics in Japanese renal transplant recipients. Eur J Clin Pharmacol. 2007 Dec;63(12):1161-9.
66 Rifampicin alters atorvastatin plasma concentration on the basis of SLCO1B1 521T>C polymorphism. Clin Chim Acta. 2009 Jul;405(1-2):49-52.
67 FDA Drug Development and Drug Interactions
68 Methotrexate-loxoprofen interaction: involvement of human organic anion transporters hOAT1 and hOAT3. Drug Metab Pharmacokinet. 2004 Oct;19(5):369-74.
69 Human organic anion transporters and human organic cation transporters mediate renal transport of prostaglandins. J Pharmacol Exp Ther. 2002 Apr;301(1):293-8.
70 Human organic anion transporters and human organic cation transporters mediate renal antiviral transport. J Pharmacol Exp Ther. 2002 Mar;300(3):918-24.
71 Identification and characterization of human organic anion transporter 3 expressing predominantly in the kidney. Mol Pharmacol. 2001 May;59(5):1277-86.
72 Prediction of the overall renal tubular secretion and hepatic clearance of anionic drugs and a renal drug-drug interaction involving organic anion transporter 3 in humans by in vitro uptake experiments. Drug Metab Dispos. 2011 Jun;39(6):1031-8.
73 Murine renal organic anion transporters mOAT1 and mOAT3 facilitate the transport of neuroactive tryptophan metabolites. Am J Physiol Cell Physiol. 2005 Nov;289(5):C1075-84.
74 Organic anion transporter 3 is involved in the brain-to-blood efflux transport of thiopurine nucleobase analogs. J Neurochem. 2004 Aug;90(4):931-41.
75 Transporter-mediated influx and efflux mechanisms of pitavastatin, a new inhibitor of HMG-CoA reductase. J Pharm Pharmacol. 2005 Oct;57(10):1305-11.
76 The contribution of organic anion transporters OAT1 and OAT3 to the renal uptake of rosuvastatin. J Pharmacol Exp Ther. 2007 Sep;322(3):1221-7.
77 Expression of organic anion transporter 2 in the human kidney and its potential role in the tubular secretion of guanine-containing antiviral drugs. Drug Metab Dispos. 2012 Mar;40(3):617-24.
78 LST-2, a human liver-specific organic anion transporter, determines methotrexate sensitivity in gastrointestinal cancers. Gastroenterology. 2001 Jun;120(7):1689-99.
79 Effect of pregnane X receptor ligands on transport mediated by human OATP1B1 and OATP1B3. Eur J Pharmacol. 2008 Apr 14;584(1):57-65.
80 Influence of non-steroidal anti-inflammatory drugs on organic anion transporting polypeptide (OATP) 1B1- and OATP1B3-mediated drug transport. Drug Metab Dispos. 2011 Jun;39(6):1047-53.
81 Relevance of conserved lysine and arginine residues in transmembrane helices for the transport activity of organic anion transporting polypeptide 1B3. Br J Pharmacol. 2010 Feb 1;159(3):698-708.
82 Impact of OATP transporters on pharmacokinetics. Br J Pharmacol. 2009 Oct;158(3):693-705.
83 Therapeutic targeting of 3',5'-cyclic nucleotide phosphodiesterases: inhibition and beyond. Nat Rev Drug Discov. 2019 Oct;18(10):770-796.
84 In vitro and in vivo effects of the phosphodiesterase-III inhibitor enoximone on malignant hyperthermia-susceptible swine. Anesthesiology. 2003 Apr;98(4):944-9.
85 Olprinone: a phosphodiesterase III inhibitor with positive inotropic and vasodilator effects. Cardiovasc Drug Rev. 2002 Fall;20(3):163-74.
86 Effects of amrinone on hepatic ischemia-reperfusion injury in rats. J Hepatol. 2002 Jul;37(1):31-8.
87 The atypical anxiolytic drug, tofisopam, selectively blocks phosphodiesterase isoenzymes and is active in the mouse model of negative symptoms of psychosis. J Neural Transm (Vienna). 2010 Nov;117(11):1319-25.
88 Company report (MediciNova)
89 Efficacy and safety of RPL554, a dual PDE3 and PDE4 inhibitor, in healthy volunteers and in patients with asthma or chronic obstructive pulmonary disease: findings from four clinical trials.Lancet Respir Med.2013 Nov;1(9):714-27.
90 Effects of the positive inotropic agent Org 30029 on developed force and aequorin light transients in intact canine ventricular myocardium. Circ Res. 1993 Mar;72(3):597-606.
91 Topical fat reduction from the waist. Diabetes Obes Metab. 2007 May;9(3):300-3.
92 Hydroxyurea compared with anagrelide in high-risk essential thrombocythemia. N Engl J Med. 2005 Jul 7;353(1):33-45.
93 Inhibitors of cyclic AMP phosphodiesterase. 2. Structural variations of N-cyclohexyl-N-methyl-4-[(1,2,3,5-tetrahydro- 2-oxoimidazo[2,1-b]quinazolin... J Med Chem. 1987 Feb;30(2):303-18.
94 Design, synthesis and biological evaluation of 6-(benzyloxy)-4-methylquinolin-2(1H)-one derivatives as PDE3 inhibitors. Bioorg Med Chem. 2010 Jan 15;18(2):855-62.
95 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
96 Cardiotonic agents. 9. Synthesis and biological evaluation of a series of (E)-4,5-dihydro-6-[2-[4-(1H-imidazol-1-yl)phenyl]ethenyl]-3 (2H)-pyridazi... J Med Chem. 1989 Feb;32(2):342-50.
97 3,4-Dihydroquinolin-2(1H)-ones as combined inhibitors of thromboxane A2 synthase and cAMP phosphodiesterase. J Med Chem. 1992 Feb 21;35(4):620-8.
98 Pharmacological profile of LAS 31180, a new inotropic/vasodilator quinolone derivative. Arzneimittelforschung. 2000 Nov;50(11):980-6.
99 Inhibitors of blood platelet cAMP phosphodiesterase. 3. 1,3-Dihydro-2H-imidazo[4,5-b]quinolin-2-one derivatives with enhanced aqueous solubility. J Med Chem. 1992 Jul 10;35(14):2688-96.
100 Product Information. Tibsovo (ivosidenib). Agios Pharmaceuticals, Cambridge, MA.
101 Canadian Pharmacists Association.
102 Cerner Multum, Inc. "UK Summary of Product Characteristics.".
103 Product Information. Xospata (gilteritinib). Astellas Pharma US, Inc, Deerfield, IL.
104 Product Information. Sirturo (bedaquiline). Janssen Pharmaceuticals, Titusville, NJ.
105 Product Information. Arcapta Neohaler (indacaterol). Novartis Pharmaceuticals, East Hanover, NJ.
106 Bengtsson B, Fagerstrom PO "Extrapulmonary effects of terbutaline during prolonged administration." Clin Pharmacol Ther 31 (1982): 726-32. [PMID: 7042176]
107 Ball P "Quinolone-induced QT interval prolongation: a not-so-unexpected class effect." J Antimicrob Chemother 45 (2000): 557-9. [PMID: 10797074]
108 Hedaya MA, El-Afify DR, El-Maghraby GM "The effect of ciprofloxacin and clarithromycin on sildenafil oral bioavailability in human volunteers." Biopharm Drug Dispos 27 (2006): 103-10. [PMID: 16372380]
109 Product Information. Daurismo (glasdegib). Pfizer U.S. Pharmaceuticals Group, New York, NY.
110 Alderman CP, Moritz CK, Ben-Tovim DI "Abnormal platelet aggregation associated with fluoxetine therapy." Ann Pharmacother 26 (1992): 1517-9. [PMID: 1482806]
111 Product Information. Ofev (nintedanib). Boehringer Ingelheim, Ridgefield, CT.
112 Price AJ, Frcpath DO "Is there a clinical interaction between low molecular weight heparin and non-steroidal analgesics after total hip replacement?" Ann R Coll Surg Engl 77 (1995): 395. [PMID: 7486773]
113 Cerner Multum, Inc. "Canadian Product Information.".
114 Product Information. Xarelto (rivaroxaban). Bayer Inc, Toronto, IA.
115 Product Information. Panhematin (hemin). Recordati Rare Diseases Inc, Lebanon, NJ.
116 Heck AM, DeWitt BA, Lukes AL "Potential interactions between alternative therapies and warfarin." Am J Health Syst Pharm 57 (2000): 1221-7 quiz 1228-30. [PMID: 10902065]
117 Product Information. Austedo (deutetrabenazine). Teva Pharmaceuticals USA, North Wales, PA.
118 Product Information. Ingrezza (valbenazine). Neurocrine Biosciences, Inc., San Diego, CA.
119 Product Information. Priftin (rifapentine). Hoechst Marion-Roussel Inc, Kansas City, MO.
120 Product Information. Rukobia (fostemsavir). ViiV Healthcare, Research Triangle Park, NC.
121 Product Information. Juxtapid (lomitapide). Aegerion Pharmaceuticals Inc, Cambridge, MA.
122 Product Information. Lorbrena (lorlatinib). Pfizer U.S. Pharmaceuticals Group, New York, NY.
123 Product Information. Tagrisso (osimertinib). Astra-Zeneca Pharmaceuticals, Wilmington, DE.
124 Abernethy DR, Wesche DL, Barbey JT, et al. "Stereoselective halofantrine disposition and effect: concentration-related QTc prolongation." Br J Clin Pharmacol 51 (2001): 231-7. [PMID: 11298069]
125 Harper KM, Knapp DJ, Criswell HE, Breese GR "Vasopressin and alcohol: A multifaceted relationship." Psychopharmacology (Berl) 235 (2018): 3363-79. [PMID: 32936259]
126 Caruso V, Iacoviello L, Di Castelnuovo A, et.al "Thrombotic complications in childhood acute lymphoblastic leukemia: a meta-analysis of 17 prospective studies comprising 1752 pediatric patients." Blood 108 (2006): 2216-22. [PMID: 16804111]
127 Ohnishi K, Yoshida H, Shigeno K, et al. "Prolongation of the QT interval and ventricular tachycardia in patients treated with arsenic trioxide for acute promyelocytic leukemia." Ann Intern Med 133 (2000): 881-5. [PMID: 11103058]
128 Product Information. Calquence (acalabrutinib). Astra-Zeneca Pharmaceuticals, Wilmington, DE.
129 Agencia Espaola de Medicamentos y Productos Sanitarios Healthcare "Centro de informacion online de medicamentos de la AEMPS - CIMA.".
130 Product Information. Iclusig (ponatinib). Ariad Pharmaceuticals Inc, Cambridge, MA.
131 Product Information. Braftovi (encorafenib). Array BioPharma Inc., Boulder, CO.
132 Cerner Multum, Inc. "Australian Product Information.".
133 Product Information. Zeposia (ozanimod). Celgene Corporation, Summit, NJ.
134 Product Information. Sprycel (dasatinib). Bristol-Myers Squibb, Princeton, NJ.
135 Product Information. Brukinsa (zanubrutinib). BeiGene USA, Inc, San Mateo, CA.
136 Product Information. Acular (ketorolac). Allergan Inc, Irvine, CA.
137 Product Information. Nuplazid (pimavanserin). Accelis Pharma, East Windsor, NJ.
138 Product Information. Xeglyze (abametapir topical). Dr. Reddy's Laboratories Inc, Upper Saddle River, NJ.
139 Product Information. Macrilen (macimorelin). Aeterna Zentaris, Charleston, SC.
140 Product Information. Xenleta (lefamulin). Nabriva Therapeutics US, Inc., King of Prussia, PA.
141 Product Information. Flolan (epoprostenol). Glaxo Wellcome, Research Triangle Park, NC.
142 Product Information. Prograf (tacrolimus). Fujisawa, Deerfield, IL.
143 Product Information. Barhemsys (amisulpride). Acacia Pharma, Inc, Indianapolis, IN.
144 Product Information. Cometriq (cabozantinib). Exelixis Inc, S San Francisco, CA.
145 Iannini PB "Cardiotoxicity of macrolides, ketolides and fluoroquinolones that prolong the QTc interval." Expert Opin Drug Saf 1 (2002): 121-8. [PMID: 12904146]
146 Product Information. Bevyxxa (betrixaban). Portola Pharmaceuticals, South San Francisco, CA.